Christine is a public C-suite executive who helps life science and biopharma companies build and scale organizations through critical inflection points in their business by developing and executing strategies to increase overall valuation through balanced and responsible growth. Through her broad experience, she has led companies through pivotal transitions, including: seed funding through IPO, successful strategic company buyouts by big pharma, approval and launch of first-to-market diabetes drug, fundraising and CxO transitions. She is a trusted advisor to the CEO and Board on investor sentiment/activity, corporate governance, cybersecurity, risk, succession planning and executive compensation. Christine is a strong candidate for Audit and Compensation Committees based on her broad finance/investor relations and corporate and board/executive compensation experience.Currently, she is the Chief Operating Officer at Equillium, Inc. (Nasdaq: EQ), a clinical stage biotech company focused on developing medicines for autoimmune and immuno-inflammatory disorders. As an early executive at EQ, Christine was deeply involved during the company’s key inflection points – from successfully filing the first IND with the FDA to taking the company public via IPO for $72M in less than 12 months.Bio and CV available upon request.